What is it about?
It summarizes lessons learned from the use of a structured framework approach in assessing benefit-risk profile of new therapeutics for Marketing Authorization Applications
Featured Image
Why is it important?
Sponsors can apply these approaches to incorporate benefit-risk assessments into their marketing authorization applications. Further shared learning and benchmarking among the pharmaceutical industry will be necessary to further advance the science and practice of benefit-risk assessment.
Perspectives
Read the Original
This page is a summary of: Implementation of Structured Benefit-Risk Assessments in Marketing Authorization Applications, Therapeutic Innovation & Regulatory Science, July 2016, SAGE Publications,
DOI: 10.1177/2168479016656898.
You can read the full text:
Contributors
The following have contributed to this page